Company Description
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide.
The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions.
In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com.
Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 1989 |
| IPO Date | Aug 8, 2007 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 3,800 |
| CEO | Joseph Kiani |
Contact Details
Address: 52 Discovery Irvine, California 92618 United States | |
| Phone | 949 297 7000 |
| Website | masimo.com |
Stock Details
| Ticker Symbol | MASI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000937556 |
| CUSIP Number | 574795100 |
| ISIN Number | US5747951003 |
| Employer ID | 33-0368882 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Joseph E. Kiani | Founder, Chief Executive Officer and Chairman |
| Micah Young | Executive Vice President and Chief Financial Officer |
| Bilal Muhsin | Chief Operating Officer |
| Thomas Samuel McClenahan | Executive Vice President, General Counsel and Corporate Secretary |
| Tao Leopold Levy | Executive Vice President of Business Development |
| Paul Hataishi | Senior Vice President and Chief Accounting Officer |
| Yongsam Lee | Executive Vice President and Chief Information Officer |
| Dr. Steven J. Barker | Chairman of Scientific Advisory Board and Chief Science Officer |
| Eli Kammerman | Vice President of Business Development and Investor Relations |
| Anand Sampath | Executive Vice President of Operations and Clinical Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 9, 2024 | DFAN14A | Filing |
| Sep 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 6, 2024 | DFAN14A | Filing |
| Sep 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 30, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |